Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

Understanding Your Diagnosis: The Basics of ET

At a Glance

Essential thrombocythemia (ET) is a slow-growing, chronic blood cancer where the bone marrow overproduces platelets. While the condition is lifelong, it is highly manageable. Treatment focuses on preventing blood clots, allowing many patients to enjoy a normal life expectancy.

Receiving a diagnosis of Essential Thrombocythemia (ET) can feel overwhelming. It is natural to feel a mix of shock, fear, and confusion. You may have heard terms like “rare disease” or “cancer,” which are heavy words to carry. It is important to know that while your life has changed, many people with ET lead full, active lives for decades after their diagnosis [1][2].

What is Essential Thrombocythemia?

Essential Thrombocythemia (ET) is a rare, chronic blood cancer that belongs to a group of diseases called Myeloproliferative Neoplasms (MPNs) [3][4]. In a healthy body, the bone marrow produces a controlled number of blood cells. In ET, a change (mutation) in the DNA of a blood-forming stem cell causes the bone marrow to produce too many platelets (thrombocytes), which are the cells responsible for blood clotting [3][5].

While it is classified as a “cancer” because it involves the uncontrolled growth of cells, it behaves very differently from what most people imagine when they hear that word. It is a slow-growing, manageable condition [1].

Three Facts to Stabilize You

When you are first diagnosed, your mind may jump to the worst-case scenarios. These three evidence-based facts can help ground you:

  1. Normal Life Expectancy: For many people with ET, life expectancy is very close to that of the general population [1][6][7].
  2. Manageable Risk: The primary concern with ET is the risk of blood clots (thrombosis), but this risk is manageable through targeted medication and lifestyle changes [8][9].
  3. Slow Progression: While ET is a chronic (long-term) condition, it often remains stable for many years. Only a small percentage of cases progress to more aggressive forms of blood disease [6][10].

Why Treatment Focuses on Prevention

Because ET is a chronic condition, the goal of treatment is not to “cure” the disease in the traditional sense. Instead, doctors focus on symptom management and risk reduction [8].

Current therapies are designed to prevent “events” like blood clots or excessive bleeding rather than eradicating the underlying cells entirely [8][11]. Your care team will use risk stratification—a way of grouping patients based on age, history of clots, and specific genetic mutations—to decide which treatments are right for you [12][13].

Common Terms You May Hear

  • Platelets: Small cell fragments in the blood that help it clot. In ET, these are overproduced [3].
  • Thrombosis: The formation of a blood clot inside a blood vessel, which can block normal blood flow [8].
  • Driver Mutations: Specific genetic changes (like JAK2, CALR, or MPL) that “drive” the overproduction of cells. Knowing which one you have helps your doctor tailor your care [14][15].
  • Cytoreductive Therapy: Medications used to actively lower the number of cells (like platelets) in your bloodstream [13][16].

Looking Ahead

ET is a journey that requires ongoing monitoring, but it is a journey you do not have to walk alone. By working closely with a hematologist—specifically one who specializes in MPNs—you can develop a personalized plan that allows you to manage the risks and focus on living your life.

Common questions in this guide

Is essential thrombocythemia a type of cancer?
Yes, essential thrombocythemia is classified as a rare, chronic blood cancer. However, unlike what many people imagine when they hear the word cancer, it is generally a slow-growing and highly manageable condition.
What is the main health risk of having ET?
The primary concern with this condition is the increased risk of developing blood clots, also known as thrombosis. Overproduced platelets can cause clots that block normal blood flow, making risk management a top priority for your care team.
What are driver mutations in essential thrombocythemia?
Driver mutations are specific genetic changes, such as JAK2, CALR, or MPL, that cause your bone marrow to overproduce blood cells. Identifying which specific mutation you have helps your doctor tailor the most effective treatment plan for you.
How is essential thrombocythemia treated?
Because ET is a chronic condition, treatment is not aimed at a traditional cure but rather at managing symptoms and reducing your risk of blood clots. This may involve cytoreductive therapy, which uses medications to actively lower the number of platelets in your bloodstream.
Will my ET progress to a worse disease?
While ET is a lifelong condition, it often remains stable for decades. Only a very small percentage of cases progress to more aggressive forms of blood disease, which is why regular monitoring by a hematologist is important.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific driver mutation (JAK2, CALR, or MPL), and how does it influence my treatment plan?
  2. 2.Has a hematopathologist confirmed my diagnosis is ET and not pre-fibrotic myelofibrosis?
  3. 3.Based on my age and history, am I considered low, intermediate, or high risk for a blood clot?
  4. 4.What specific symptoms should I watch for that might indicate a blood clot?
  5. 5.How often will we monitor my platelet levels and overall cardiovascular health over time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.

    Accurso V, Santoro M, Mancuso S, et al.

    Clinical medicine insights. Blood disorders 2020; (13()):2634853520978210 doi:10.1177/2634853520978210.

    PMID: 33447121
  2. 2

    Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.

    Htun HL, Lian W, Wong J, et al.

    Cancer epidemiology 2022; (79()):102175 doi:10.1016/j.canep.2022.102175.

    PMID: 35569302
  3. 3

    Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

    Hasselbalch HC

    Haematologica 2019; (104(11)):2119-2125 doi:10.3324/haematol.2019.229039.

    PMID: 31666340
  4. 4

    Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

    Shallis RM, Zeidan AM, Wang R, Podoltsev NA

    Hematology/oncology clinics of North America 2021; (35(2)):177-189 doi:10.1016/j.hoc.2020.11.005.

    PMID: 33641862
  5. 5

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  6. 6

    Austrian recommendations for the management of essential thrombocythemia.

    Buxhofer-Ausch V, Heibl S, Sliwa T, et al.

    Wiener klinische Wochenschrift 2021; (133(1-2)):52-61 doi:10.1007/s00508-020-01761-3.

    PMID: 33215234
  7. 7

    Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

    Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

    European journal of haematology 2026; doi:10.1111/ejh.70141.

    PMID: 41717866
  8. 8

    Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

    Verstovsek S, Yu J, Scherber RM, et al.

    Leukemia & lymphoma 2022; (63(3)):694-702 doi:10.1080/10428194.2021.1992756.

    PMID: 34689695
  9. 9

    Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

    Pemmaraju N, Gerds AT, Yu J, et al.

    Leukemia research 2022; (115()):106809 doi:10.1016/j.leukres.2022.106809.

    PMID: 35220060
  10. 10

    Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

    Bartels S, Vogtmann J, Schipper E, et al.

    European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

    PMID: 33460496
  11. 11

    How I treat essential thrombocythemia.

    Rumi E, Cazzola M

    Blood 2016; (128(20)):2403-2414 doi:10.1182/blood-2016-05-643346.

    PMID: 27561316
  12. 12

    Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

    Santoro M, Accurso V, Mancuso S, et al.

    Hematological oncology 2019; (37(4)):434-437 doi:10.1002/hon.2670.

    PMID: 31465530
  13. 13

    [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].

    Iványi JL, Marton É, Plander M, Szendrei T

    Orvosi hetilap 2016; (157(9)):336-41 doi:10.1556/650.2016.30323.

    PMID: 26895801
  14. 14

    Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

    Abdelghani M, Hammami H, Zidi W, et al.

    Journal of clinical laboratory analysis 2022; (36(8)):e24522 doi:10.1002/jcla.24522.

    PMID: 35754115
  15. 15

    From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

    Stein BL, Martin K

    Hematology. American Society of Hematology. Education Program 2019; (2019(1)):397-406 doi:10.1182/hematology.2019001318.

    PMID: 31808903
  16. 16

    Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

    Ito T, Hashimoto Y, Tanaka Y, et al.

    European journal of haematology 2019; (103(2)):116-123 doi:10.1111/ejh.13265.

    PMID: 31107982

This page provides educational information about an essential thrombocythemia diagnosis. Always consult your hematologist or oncologist to discuss your specific condition, risks, and personalized treatment plan.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.